Mizuho sees 13% upside in Merck in premarket analyst action

|About: Inogen, Inc. (INGN)|By:, SA News Editor

CannTrust Holdings (NYSE:CTST) initiated with Buy rating and $7 (41% upside) price target at Citigroup.

Marker Therapeutics (NASDAQ:MRKR) initiated with Outperform rating and $15 (91% upside) price target at Oppenheimer.

Merck (NYSE:MRK) initiated with Buy rating and $97 (13% upside) price target at Mizuho Securities.

Inogen (NASDAQ:INGN) downgraded to Underperform with a $72 (10% upside) price target to JPMorgan citing limited upside compared to peers.

Subscribe for full text news in your inbox